Experience of Femoston Treatment in Perimenopausal Women Receiving Oral Corticosteroid Therapy

Abstract

Chronic oral corticosteroid therapy, which is widely used for the treatment of bronchial asthma, dermatological, rheumatic diseases, systemic diseases of the connective tissue, etc., is often a psychological obstacle to the appointment of hormone replacement therapy (HRT) for women in menopause. At the same time, the appointment of estrogenic drugs for this category of patients in some cases is necessary, since by reducing climacteric symptoms, stopping urogenital disorders and increasing the level of bone mass, HRT can significantly improve the quality of life.

Keywords

femoston treatment / perimenopausal woman / oral corticosteroid therapy / estrogenic drug / femoston

References

[1] Балан В.Е., Вихляева Е.М., Зайдиева Я.З. и соавт. Менопаузальный синдром (клиника, диагностика, профилактика и заместительная гормональная терапия).— М., 1996. -64 с.

[2] Barrett-Connor Е., Bush Т. L. Estrogen and coronary heart disease in women // Journal of the American Medical Association. - 1991. - Vol. 265. - P. 1861-1867.

[3] Bush T. L., Miller-Bass K. Estrogen therapy and cardiovascular disease: do the benefits outweigh the risks? // Clinical Obstetrics and Gynecology. -1991. - Vol. 5. - P. 889-913.

[4] Crook D., Stevenson J.C., Siddle N.C. Dydrogesterone fails to oppose the effects of estrogen on serum lipoprotein metabolism // Presented at the Vllth International Congress on the Menopause, Stockholm, Sweden. 1993 (Abstract).

[5] Lees B., Stevenson J.C. The Prevention of Osteoporosis Using Sequential Low-Dose Hormon Replacement Therapy with Estradiol-17b and Dydrogesterone // Osteoporosis International. - 2001. - Vol. 12. - P. 251-258.

[6] Lippuner K., Haenggi W., Birkhaeuser M.H., Jaeger P.H. Prevention of postmenopausal osteoporosis in a comparative study with tibolone, oral estradiol and transdermal estradiol // Wold Congress on Osteoporosis: Amsterdam, 1996. - Vol. 6 (suppl. 1). - P. 230 (Abstact).

[7] Lobo R.A., Speroff L. International consensus conferens on postmenopausal hormon therapy and the cardiovaskular system // Fertility and Sterility. -1994. - Vol. 61. - P. 592-595.

[8] Lukert B.P., Raisz L.G. Glucocorticoid-indused osteoporosis: pathogenesis and management //Ann. Intern. Med. - 1990. - Vol. 112. - P. 648-651.

[9] National Osteoporosis Foundation. Osteoporosis: Review of the Evidence for Prevention, Diagnosis and Treatment and Cost-Effective Analysis. // Osteoporosis Int. - 1998. - Vol. 8. (SuppL4).

[10] Siddle N., Jesinger D., Whitehead M. et al. Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone // British Journal of Obstetrics and Gynecology. -1990. - Vol. 97. - P. 1093-1100.

[11] Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidens // Preventative Medicine. - 1991. - Vol. 20. - P. 47-63.

[12] Van der Mooren M.J., Demacker P.N.M., Thonas C.M.S. et al. A 2-year study on the beneficial effects of 17b- estradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavorable effects of dydrogesterone // European Journal of Obstetrics, Gynecology and Reproductive Biology. - 1993. - Vol. 52. - P. 117-123.

[13] Voetberg G.A., Netelenbos J.C., Kenemans P. et al. Estrogen replacement therapy continuously combined with four dosages of dydrogesterone; effect on calcium and lipid metabolism // Journal of Clinical Endocrinology and Metabolism. -1994. - Vol. 79. - P. 1465-1469.

RIGHTS & PERMISSIONS

Eсо-Vector